Artificial Intelligence and Machine Learning in Computational Nanotoxicology: Unlocking and Empowering Nanomedicine
Искусственный интеллект и машинное обучение в вычислительной нанотоксикологии: раскрытие потенциала и расширение возможностей наномедицины
2020-07-06
SCID: 54.1/xyaquxtq
Discuss with AI
PBPK modelingcomputational nanotoxicologymachine learningnano-QSARnanomedicine
Figures from the paper
Abstract (AI)
Advances in nanomedicine, coupled with novel methods of creating advanced materials at the nanoscale, have opened new perspectives for the development of healthcare and medical products. Special attention must be paid toward safe design approaches for nanomaterial-based products. Recently, artificial intelligence (AI) and machine learning (ML) gifted the computational tool for enhancing and improving the simulation and modeling process for nanotoxicology and nanotherapeutics. In particular, the correlation of in vitro generated pharmacokinetics and pharmacodynamics to in vivo application scenarios is an important step toward the development of safe nanomedicinal products. This review portrays how in vitro and in vivo datasets are used in in silico models to unlock and empower nanomedicine. Physiologically based pharmacokinetic (PBPK) modeling and absorption, distribution, metabolism, and excretion (ADME)-based in silico methods along with dosimetry models as a focus area for nanomedicine are mainly described. The computational OMICS, colloidal particle determination, and algorithms to establish dosimetry for inhalation toxicology, and quantitative structure-activity relationships at nanoscale (nano-QSAR) are revisited. The challenges and opportunities facing the blind spots in nanotoxicology in this computationally dominated era are highlighted as the future to accelerate nanomedicine clinical translation.
Key Findings
1
AI and machine learning enhance simulation and modeling for nanotoxicology and nanotherapeutics, supporting safer nanomedicine development.
2
Computational OMICS, colloidal particle characterization, inhalation dosimetry algorithms, and nano-QSAR are highlighted as important computational approaches.
3
In silico nanomedicine relies on PBPK, ADME, and dosimetry models to predict nanoparticle behavior and support risk assessment.
4
Integrating in vitro pharmacokinetic and pharmacodynamic data with in vivo scenarios is identified as essential for developing safe nanomedicinal products.
5
The review identifies persistent blind spots and challenges in nanotoxicology while emphasizing computational methods as opportunities to accelerate clinical translation.
Research Object
nanomaterial-based medical products and their in vitro and in vivo pharmacokinetic, pharmacodynamic, toxicological, and dosimetry data
Research Subject
AI- and ML-enabled in silico modeling of nanotoxicology and nanomedicine safety, including PK/PD translation, PBPK/ADME, dosimetry, and nano-QSAR
Publication Details
Publication Date
2020-07-06
Journal
Publisher
ISSN
Cited by
333
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest